IPO registrations (S-1, F-1) · Registrants
InflaRx N.V.
- SEC CIK
- 1708688 · filings on EDGAR ↗
- Former names
- Fireman B.V. (2017–2017)
- Registration
- Form F-1, first filed 2017-10-13, last 2018-05-02; 2 initial registrations, 4 amendments
- Outcome
- Final prospectus filed 2017-11-08; declared effective 2017-11-07
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- P7
- Business address
- WINZERLAER STR. 2, Jena, 2M 07745
- Ticker
- IFRX (Nasdaq)
- EDGAR entity type
- other
- Insiders and CEO pay
- InflaRx N.V. on the corporate pages
Offering terms
- Final price
- $15.00 per share (424B4 filed 2017-11-08, an initial public offering)
- Shares sold
- 6,667,000
- Gross proceeds
- $100,005,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol IFRX
- Lead underwriters
- J.P. Morgan; Leerink Partners; BMO Capital Markets
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- SEC filer: InflaRx N.V. EXACT (CIK (EXACT))
Filings 10
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2017-10-13 | F-1 | F-1 (foreign registration) | Fireman B.V. | 0000950103-17-009967 ↗ |
| 2017-10-26 | F-1/A | F-1/A (amendment) | Fireman B.V. | 0000950103-17-010266 ↗ |
| 2017-10-30 | F-1/A | F-1/A (amendment) | Fireman B.V. | 0001193125-17-323823 ↗ |
| 2017-10-31 | F-1/A | F-1/A (amendment) | Fireman B.V. | 0001193125-17-327347 ↗ |
| 2017-11-07 | F-1/A | F-1/A (amendment) | Fireman B.V. | 0000950103-17-010902 ↗ |
| 2017-11-07 | EFFECT | EFFECT (declared effective) | Fireman B.V. | 9999999995-17-002900 ↗ |
| 2017-11-08 | 424B4 | 424B4 (final prospectus) | InflaRx N.V. | 0001193125-17-337427 ↗ |
| 2018-05-02 | F-1 | F-1 (foreign registration) | InflaRx N.V. | 0000950103-18-005705 ↗ |
| 2018-05-03 | EFFECT | EFFECT (declared effective) | InflaRx N.V. | 9999999995-18-001136 ↗ |
| 2018-05-07 | 424B4 | 424B4 (final prospectus) | InflaRx N.V. | 0000950103-18-005944 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2017-11-07 | F-1/A | registration statement | 1,110 | - | 0 | primary document; shares headline | document ↗ | |||
| 2017-11-08 | 424B4 | final prospectus | $15.00 | 6,667,000 | $100,005,000 | Nasdaq IFRX | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Brudnick Richard | Director | 1 | 2026 | ||
| Fulpius Nicolas | Director | 1 | 2026 | ||
| Gibney Anthony S | Director | 1 | 2026 | ||
| Guo Renfeng | Director,Officer | Chief Scientific Officer | 1 | 2026 | |
| Hellstrom Hege | Director | 1 | 2026 | ||
| Kubler Mark | Director | 1 | 2026 | ||
| OCarroll Derval | Officer | See Remarks | 1 | 2026 | |
| Riedemann Niels | Director,Officer | Chief Executive Officer | 1 | 2026 | |
| Taapken Thomas | Officer | Chief Financial Officer | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| SEC filer | InflaRx N.V. | SEC filers (EDGAR) | CIK (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, 2M first:
- MorphoSys AG 2M
- Affimed N.V. 2M
- Biofrontera AG 2M
- CURAXIS PHARMACEUTICAL Corp 2Q
- ONCOGENEX TECHNOLOGIES INC A1
- Aspreva Pharmaceuticals CORP A1
- Lexaria Bioscience Corp. A1
- Zymeworks BC Inc. A1
- BetterLife Pharma Inc. A1
- ABATTIS BIOCEUTICALS CORP A1
In other datasets, the same topic (Health) in 2M:
- Form D issuer: ATAI Life Sciences AG (Form D private offerings)
Interests: Pharmaceutical Preparations · Health